TEVA PHARMACEUTICAL INDUSTRIES LIMITED

TEVACIK 000081868610 fiscal years

RevenueFY2025

$17.26B4.3%

Net incomeFY2025

$1.41B186.0%

Free cash flowFY2025

$1.15B53.3%

Diluted EPSFY2025

$1.21183.4%

Trends

FY2016–FY2025 · hover a year for its filing

Revenue & net incomeRevenueNet income

net margin 1.5% → 8.2%

MarginsNet marginFCF margin

FY2025: net 8.2% · free cash flow 6.7% of revenue

Cash flowOperating cash flowFree cash flow

FY2025: $1.65B operating cash − $501.0M capex = $1.15B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity -94% (FY2017) → 18% (FY2025) · on assets 3.5%

Balance sheetLiabilitiesEquity

FY2025: $40.75B assets · $32.83B liabilities · $7.91B equity

Financial statements

Annual Quarterly

USD millions, except per-share values; share counts in millions. Hover a value for its XBRL tag and filing accession.

USD millions	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Revenue	17,258	16,544	15,846	14,925	15,878	16,659	16,887	18,271	21,853	21,903
Net income	1,410	(1,639)	(559)	(2,446)	417	(3,990)	(999)	(2,150)	(16,265)	329
Diluted EPS	1.21	(1.45)	(0.50)	(2.20)	0.38	(3.64)	(0.91)	(2.35)	(16.26)	0.07
Diluted shares	1,163	1,131	1,119	1,110	1,107	1,095	1,091	1,021	1,016	0
Operating cash flow	1,649	1,247	1,368	1,590	798	1,216	748	2,446	2,225	3,890
Capital expenditures	501	498	526	548	562	578	525	651	874	901
Free cash flow	1,148	749	842	1,042	236	638	223	1,795	1,351	2,989
Cash & equivalents	3,556	3,300	3,226	2,801	2,165	2,177	1,975	1,782	963	—
Total assets	40,748	39,326	43,479	44,011	47,666	50,640	57,470	60,683	70,615	—
Total liabilities	32,834	33,606	35,353	35,413	36,422	39,579	42,407	44,889	51,870	—
Shareholders' equity	7,910	5,373	7,506	7,804	10,278	10,026	13,972	14,707	17,359	—

As reported in SEC filings; a missing tag shows “—”, never zero. Free cash flow is operating cash flow − capex. Methodology